Depressive disorder according to DSM or ICD criteriaClinician diagnostic interview · patients with depressive disorders in children and adolescents
1 finding from 1 review
Suicide completionCompleted suicide rates · patients with depressive disorders in children and adolescents
1 finding from 1 review
Remission or response (as defined in trial) · patients with depressive disorders in children and adolescents
Second generation antidepressant probably leads to higher remission or response (as defined in trial) compared with placebo (by medication) (moderate certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with depressive disorders in children and adolescents
Second generation antidepressant may leads to higher suicide‐related outcome compared with placebo (by medication) (low certainty).
1 finding from 1 review
Depressive symptoms · patients with depressive disorders in children and adolescents
1 finding from 1 review
Response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) compared with placebo (very low certainty).
1 finding from 1 review
Remission (response plus end score 8 or less) · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes remission (response plus end score 8 or less) compared with light therapy (very low certainty).
1 finding from 1 review
Speed of onset of response · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ treatment emergent · adults with seasonal affective disorder
Fluoxetine showed no clear difference in adverse events (at least 1 treatment‐emergent adverse event) compared with light therapy (low certainty).
1 finding from 1 review
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Speed of onset of response · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall adverse events 5 weeks · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes overall adverse events 5 weeks compared with placebo (very low certainty).
1 finding from 1 review
Response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) · adults with seasonal affective disorder
Fluoxetine showed no clear difference in response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) compared with light therapy (low certainty).
1 finding from 1 review
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · adults with seasonal affective disorder
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to lower incidence of SAD (SIGH‐SAD score ≥ 20) compared with placebo (moderate certainty).
1 finding from 1 review
Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Headache · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to higher headache compared with placebo (moderate certainty).
1 finding from 1 review